In contrast, the overexpression of TMEM170B in cells MDA-MB-231 reduced protein levels of TCF4, CD44, c-Myc, and cyclin D. Through the analysis of the nuclear and cytoplasmic extracts, it can be corroborated that, the effect of TMEM170B in breast cancer is mediated by inhibition of the stabilization and translocation to the nucleus of β-catenin, It was shown that TMEM170B can directly regulate β-catenin expression independently of GSK-3β (61). The gene discussed is TMEM170B; the disease is breast carcinoma.